Global Biosimilars Market Analysis

The global biosimilars industry has been growing stupendously since the past few years. Various factors, such as increasing healthcare costs, burgeoning aging population, high pharmaceutical expenditure, and costly drugs are driving the incessant growth of the global biosimilars industry.

According to our new research report “Global Biosimilars Market Analysis”, the global biosimilars market is anticipated to grow at a CAGR of around 52% during 2010-2015. Market growth will be driven by upcoming patent expiries and the rising drugs bill that will encourage payers to address the barriers to biosimilars’ access in order to control costs. As the governments and private players have stepped in the industry across various geographical locations, the future prospects of the market shows immense opportunities to tap on.

Our thorough study on the industry indicates that the Global Biosimilars industry has witnessed a number of product launches and mergers & acquisitions in the past few years. The main focus of the companies has been to introduce effective and quality products in the market so that it gains a worldwide acceptance.

Our report has found that as far as number of biosimilars approvals is concerned, Europe holds a numero uno position in the market. However, despite having a specific regulatory patheways for biosimilars in the regions, a very limited number of players have launched their products in this region.

On the competitive front, Sandoz is presently the global market leader in biosimilars sales (the only company to have more than two biosimilar products approved) with Teva and Hospira also developing a range of biosimilar products. Meanwhile, some Indian companies are also using their experiences within the deregulated markets to produce dossiers and products suited for the regulated markets.

The report provides extensive information and rational analysis of the global biosimilars market. It has thoroughly examined current market drivers and restraints, industrial developments, and competitive landscapes to enable clients understand the market structure and its progress in the coming years. The report also provides an insight into different biosimilars marketed products along with country-wise analysis to present an overview of the developments taking place in the global biosimilars industry. Further, a review of product introductions/innovations and recent industry activity has also been covered in the report.

Global Generic Drug Industry

1. Analyst View
2. Research Methodology
3. Market Drivers & Restraints
3.1 Biotech Allies with Pharma to Discover Biosimilars
3.2 Biosimilars Approvals are on the Rise
3.3 Biogenerics: Market Entry Barriers
3.4 Rising Interests of Venture Capitalists
4. Industry Performance
4.1 Market Size
4.2 Currently Marketed Biosimilars
4.2.1 Erythropoietin
4.2.2 Human Growth Hormone
4.2.3 Recombinant Human Insulin
4.2.4 G-CSF
4.2.5 Interferons
5. Major Geographical Market
5.1 Americas
5.1.1 US
5.1.2 Canada
5.1.3 Mexico
5.2 EU
5.3 Asia Pacific
5.3.1 Korea
5.3.2 China
5.3.3 India
6. Regulatory Environment
7. Patent Expirations & Product Approvals
8. Collaborations & Acquisitions
9. Competitive Landscape
9.1 Teva
9.2 Sandoz
9.3 Hospira
9.4 Mylan
9.5 Actavis
9.6 Biocon Ltd.
9.7 Cipla Ltd.
9.8 Dr. Reddy's Laboratories Ltd.
9.9 Wockhardt Ltd.

List of Figures:

Figure 4-1: Global - Biosimilars Market (Million US$), 2010 & 2015
Figure 4-2: Global - Biosimilars Market by Segment (%), 2010
Figure 4-3: Global - Forecast for Biosimilars Market by Segment (%), 2015